Clinical pharmacology of intraperitoneal cisplatin-based chemotherapy

Matteo Conti, U. De Giorgi, V. Tazzari, F. Bezzi, C. Baccini

Research output: Contribution to journalArticlepeer-review


The management of intraperitoneal tumors, especially when confined to the peritoneal cavity and/or associated with malignant ascites, requires the use of intraperitoneal (i.p.) cisplatin-based chemotherapy. This therapeutic approach, enabling high concentrations of drug and long duration of tumor tissue exposure, while generating a systemic exposure similar to that obtained with intravenous (i.v.) infusion, significantly improves therapeutic ratio. Nowadays, as feasibility issues are easy to overcome, intraperitoneal chemotherapy provides a safe, effective treatment for the management of peritoneal disease, particularly ovarian carcinoma. In this paper we review pharmacological issues of intraperitoneal cispiatin-based chemotherapy in order to provide a ready to use information collection for clinical practice and ongoing research.

Original languageEnglish
Pages (from-to)23-25
Number of pages3
JournalJournal of Chemotherapy
Issue numberSUPPL. 5
Publication statusPublished - Nov 2004


  • Cisplatin
  • Clinical pharmacology
  • Intraperitoneal chemotherapy

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)


Dive into the research topics of 'Clinical pharmacology of intraperitoneal cisplatin-based chemotherapy'. Together they form a unique fingerprint.

Cite this